Achievement of On‑Treatment Remission With Risankizumab in Patients With Moderate‑to‑Severe Psoriasis
Year: 2025
Type: article
Abstract: A high proportion of patients with moderate-to-severe psoriasis achieved on-treatment remission with risankizumab Achievement of on-treatment remission was associated with quality-of-life improvements that were maintained through 148 weeks To obtain a PDF of this poster Scan QR code or use the following link to download an electronic version of this presentation and other AbbVie Fall Clinical 2025 scientific presentations https://abbvie1.outsystemsenterprise.com/CongressPublications/CongressHome?CongressId=b8758441
DOI: 10.25251/1ahmv830
Institutions: University of California, Los Angeles, Universidade do Porto, Hospital de Santo António, The University of Texas Southwestern Medical Center, University College Dublin, St. Vincent's University Hospital, Icahn School of Medicine at Mount Sinai, AbbVie (United States), Leiden University Medical Center, Salford Royal NHS Foundation Trust, University of Manchester, NIHR Manchester Biomedical Research Centre
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4416084872